Royalty Revenue & Cash Operating Expenses $219M in cash at June 30 and no debt Leverage from royalty revenue growth and lean operating expenses Operating structure expected to support growing profitability and cash flow 7 FINANCIAL REVIEW AND 2023 GUIDANCE 8 Q2 2023 FINANCIAL PERFORMANCE Lıgand® 1Nasdaq: LGND The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it's partners' judgment as of the date of this pr ...

Simon Latimer Slide 6 summarizes the expanded tactical approaches we use to grow our royalty portfolio. These are; one, project finance through which we provide development capital to fund clinical stage programs in return for royalty contracts on future sales; two, royalty monetization, where we purchase existing royalty rights owned by inventors, universities or companies; three, M&A, where we buy companies with valuable assets or partnerships and realize the value of those assets while rationalizing the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

And with that, I will turn it back to the operator and thank everybody for joining us today. Thank you. Operator Hey guys good afternoon. Thanks for taking the question Todd, I wanted to ask about the evolution of your thinking around strategy here especially since you took over, but of course you have been with the company for a while. Your initial comments had some nice breakout of how you are thinking about things and the Q&A has touched upon it, but I guess I want to approach it from this way. Operator ...

1 CORPORATE PRESENTATION MARCH 2023 Nasdaq: LGND 2 SAFE HARBOR STATEMENT The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it's partners' judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "projects," "could," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transitio ...

royalty generating asset portfolio and positions us for strong continued growth. Tavo, our CFO will provide more 2022 financial results, as well as our increased '23 financial guidance. Rylaze marketed by Jazz is a recombinant Erwinia asparaginase used for a component of a multi-agent chemotherapeutic regimen for the treatment of children and adults with ALL or LBL. This product continues to do well in the market that was historically constrained by supply issues for the previous standard of care product. S ...

November 2022 Nasdaq: LGND Ligand Corporate Presentation SAFE HARBOR STATEMENT The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it's partners' judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "projects," "could," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, withou ...

Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO Matthew Korenberg - President & CFO Octavio Espinoza - CFO Conference Call Participants Joseph Pantginis - HC Wainwright Larry Solow - CJS Securities Matthew Hewitt - Craig-Hallum Capital Group Scott Henry - ROTH Capital Operator Good afternoon. My name is Vinesin, and I will be your conference actor today. At this time, I would like to welc ...

Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO & Executive Director Matthew Korenberg - EVP, Finance & CFO Matthew Foehr - President & COO Conference Call Participants Peter Lukas - CJS Securities Matthew Hewitt - Craig-Hallum Operator Welcome to the Ligand Pharmaceuticals Second Quarter Earnings Conference Call. My name is Vanessa, and I will be your operator for today's call. [Operator I ...